Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cofactors and Coenzymes01:24

Cofactors and Coenzymes

12.5K
Enzymes are proteins made of amino acids. The functional group of each constituent amino acid catalyzes a wide variety of chemical reactions via ionic interactions or acid-base reactions. However, amino acids cannot catalyze oxidation-reduction and group transfer reactions and need to be aided by non-protein components called cofactors. Cofactors are also referred to as the chemical teeth of an enzyme.
Cofactors can be metallic ions or organic molecules called coenzymes. These types of helper...
12.5K
Cofactors and Coenzymes01:27

Cofactors and Coenzymes

86.7K
Enzymes require additional components for proper function. There are two such classes of molecules: cofactors and coenzymes. Cofactors are metallic ions and coenzymes are non-protein organic molecules. Both of these types of helper molecule can be tightly bound to the enzyme or bound only when the substrate binds.
86.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

18.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.3K
Electron Transport Chain: Complex III and IV01:43

Electron Transport Chain: Complex III and IV

8.9K
During the electron transport chain, electrons from NADH and FADH2 are first transferred to complexes I and II, respectively. These two complexes then transfer the electrons to ubiquinol, which carries them further to complex III. Complex III passes the electrons across the intermembrane space to Cyt c, which carries them further to complex IV. Complex IV donates electrons to oxygen and reduces it to water. As electrons pass through complexes I, III, and IV, the energy released aids the pumping...
8.9K
Role of Reduced Coenzymes NADH and FADH₂01:29

Role of Reduced Coenzymes NADH and FADH₂

16.0K
The energy released from the breakdown of the chemical bonds within nutrients can be stored either through the reduction of electron carriers or in the bonds of adenosine triphosphate (ATP). In living systems, a small class of compounds functions as mobile electron carriers, molecules that bind to and shuttle high-energy electrons between compounds in pathways. The principal electron carriers that will be considered originate from the B vitamin group and are derivatives of nucleotides; they are...
16.0K
Vitamins01:30

Vitamins

2.2K
Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of IVUS Guidance on Clinical and Procedural Outcomes in Intracoronary Brachytherapy.

JACC. Advances·2026
Same author

Sex-Based Differences in Long-Term Outcomes Following Intravascular Brachytherapy for In-Stent Restenosis.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Intravascular brachytherapy vs. drug-coated balloons for in-stent restenosis in patients with diabetes.

Frontiers in cardiovascular medicine·2026
Same author

Impact of diabetes in long-term outcomes following intravascular brachytherapy for in-stent restenosis.

Cardiovascular revascularization medicine : including molecular interventions·2025
Same author

Intravascular Brachytherapy for In-Stent Restenosis in Patients With Chronic Kidney Disease.

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Lesion Preparation Before Coronary Intravascular Brachytherapy: A Comparison of Plain Balloon Versus Cutting/Scoring Balloon Angioplasty.

Journal of the Society for Cardiovascular Angiography & Interventions·2025

Related Experiment Video

Updated: Jan 4, 2026

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

2.2K

Coenzyme Q10.

Albert E Raizner1

  • 1HOUSTON METHODIST DEBAKEY HEART AND VASCULAR CENTER, HOUSTON METHODIST HOSPITAL, HOUSTON, TEXAS.

Methodist Debakey Cardiovascular Journal
|November 6, 2019
PubMed
Summary
This summary is machine-generated.

Coenzyme Q10 (CoQ10) supplementation shows promise for statin-associated myopathy syndrome (SAMS) and congestive heart failure (CHF). Evidence supports CoQ10 use in SAMS, with emerging data suggesting benefits in CHF management.

Keywords:
CoQ10coenzyme Q10congestive heart failurestatin myopathystatin-associated muscle symptomsubiquinolubiquinone

More Related Videos

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.5K
Quantification of Coenzyme A in Cells and Tissues
08:51

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

8.8K

Related Experiment Videos

Last Updated: Jan 4, 2026

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

2.2K
Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.5K
Quantification of Coenzyme A in Cells and Tissues
08:51

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

8.8K

Area of Science:

  • Nutritional Biochemistry
  • Cardiology
  • Pharmacology

Background:

  • Coenzyme Q10 (CoQ10) is a vital endogenous antioxidant and electron carrier.
  • It is a popular dietary supplement with potential therapeutic applications.
  • This review examines CoQ10's properties and clinical utility.

Purpose of the Study:

  • To review the chemical, metabolic, and physiological properties of CoQ10.
  • To evaluate scientific data and clinical trials on CoQ10 for statin-associated myopathy syndrome (SAMS).
  • To assess the role of CoQ10 in congestive heart failure (CHF).

Main Methods:

  • Literature review of CoQ10's properties.
  • Analysis of clinical trials and meta-analyses concerning CoQ10 in SAMS.
  • Evaluation of evidence for CoQ10's use in CHF, including the Q-SYMBIO trial.

Main Results:

  • Meta-analyses suggest CoQ10 use is beneficial for SAMS, despite conflicting trial conclusions.
  • Limited large-scale randomized trial data exists for CoQ10 in CHF with contemporary treatments.
  • The Q-SYMBIO trial indicates a potential adjunctive role for CoQ10 in CHF.

Conclusions:

  • The overall evidence supports CoQ10 supplementation for managing SAMS.
  • CoQ10 may serve as an adjunctive therapy in congestive heart failure.
  • Recommendations for CoQ10 use in these conditions are provided.